“We need to know what peptides are presented on the surface of cells. The only tool for this is mass spectrometry.”
- Robert Salzler, Regeneron
12
2023年2月15日——美国马萨诸塞州Littleton。New Objective CEO Mike Lee和联合创始人、总裁Emily Ehrenfeld举行了一场线上研讨会，展示了再生元制药将加热款PicoChip作为免疫多肽研究的标准化平台的应用。正如Emily在开幕致辞中所说：“我们所做的一切都是以患者的利益为出发点。”
February 15, 2023 – Littleton, MA (USA) Mike Lee, CEO, together with Emily Ehrenfeld, Co-Founder and President, New Objective hosted an event featuring the heated PicoChip as a standardized platform for Immunopeptidomic research conducted at Regeneron. As Emily shared during the opening remarks: “The benefit of the patient is at the forefront of all we do.”
12
New Objective副总裁Amanda Berg介绍了由New Objective开发的加热款PicoChip ——"一个易于使用的解决方案，可以将emitters转换为有意义的结果.” Picochips为临床蛋白质组学的各类应用提供高性能、稳健、可重现性和可靠性的解决方案。
Amanda Berg, Vice President, New Objective, introduced the Heated PicoChip platform developed by New Objective - “An easy-to-use solution that transforms emitters to meaningful results.” The PicoChips deliver a high performance, robust, reproducible and reliable solution for clinical proteomic applications.
12
New Objective产品经理Helena Svobodova向大家介绍了Robert Salzler并对其致以热烈的欢迎。Helena介绍了Robert和New Objective关系的起始。
“这一切始于Mike给Robert的一个电话，两人共同携手建立一个工业化平台。今天，我们一起为Robert在免疫肽技术方面所做出的贡献而庆祝。”
Helena Svobodova, Product Manager, New Objective welcomed and introduced Robert Salzler and about the beginning of his relationship with New Objective. “It started with a call from Mike to Robert, and working together on an industrialized platform. Today we are celebrating Robert’s work on immunopeptidomics.”
12
Robert Salzle, 再生元制药，团队负责人，负责肿瘤、传染病和自身免疫的免疫肽抗原发现和靶向研究。他介绍了Regeneron开发的各种抗体疗法，以解决当今最紧迫的健康问题，每个临床研究阶段当以患者为先。
Robert Salzler, Team Leader for Immunopeptidomics (Discovery and Targeted) for Oncology, Infectious Disease and Autoimmunity, Regeneron shared the overview of various antibody therapies developed at Regeneron to address some of the most pressing health issues today by putting patient first at every stage of the clinical research.
12
Robert强调了他对于New Objective产品的使用体验以及如何从一个简单的对喷针的需求发展为共同开发最先进解决方案的历程。
——“我们对这些感到非常满意，它们将成为我们系统的基础。“
——“加热款PicoChip可以持续大约一个月，几乎没有干扰。”
Robert highlighted his experience with New Objective products and how the relationship with New Objective developed from a simple emitter request to working with state of the art solutions. The Heated PicoChip columns deliver the desired results - “Very happy with these - will be the foundation of our system.” “The heated PicoChip lasts about a month with little to no interference.”
12
Robert随后介绍了他的同事Mayank Srivastava，科学家，蛋白质组学和免疫多肽学，再生元制药。Mayank为最近发表的论文Proteogenomic identification of Hepatitis B virus (HBV) genotype-specific HLA-I restricted peptides from HBV-positive patient liver tissues.的第一作者。他谈到了HBV病毒的基因变异，当与患者的基因差异相结合时，使得开发有效抗体变得非常困难。
——“这种病毒随机整合到人类基因组中。”
Robert then introduced his colleague Mayank Srivastava, Scientist, Proteomics and Immunopeptidomics at Regeneron and lead researcher on the recent publication on Proteogenomic identification of Hepatitis B virus (HBV) genotype-specific HLA-I restricted peptides from HBV-positive patient liver tissues. Mayank talked about the genomic variability of the HBV virus which when combined with the genomic difference in the patients make it very difficult to develop effective antibodies. “This virus integrates into the human genome randomly.”
The above artical can be found at: https://pubmed.ncbi.nlm.nih.gov/36582233/
12
为了解决这些挑战，Regeneron开发了一个患者特异性的病毒肽数据库，与HLA基因型一起用于靶点选择。如Mayank所说：“质谱是一种发现引擎！”
To address these challenges, Regeneron developed a patient specific database of viral peptides which along with HLA genotypes are used for target selection. As Mayank stated: “Mass spec is a discovery engine!”
12
我们邀请您加入一起庆祝我们的客户及合作伙伴所做出的研究成果的活动。我们对这些客户和合作伙伴一直建立长效的沟通机制，期待下一个就是您！
引自Robert：“我们正在分享一个项目，但我们拥有数百个项目。”
期待我们的持续讨论！
We invite you to join the ongoing communication and celebration of research featuring our customers and collaborators. To quote Robert: “We are sharing one project – but we have hundreds of projects.” We look forward to our ongoing discussion.
END
Tel: 18100095051 (微信同号）
首页
